ClinicalTrials.gg
CompletedNCT04789174SHARPUpdated Jan 26, 2026Results posted

Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study

A Phase 4 interventional study of Solriamfetol and Placebo in Excessive Daytime Sleepiness, Obstructive Sleep Apnea and Impaired Cognitive Function, sponsored by Axsome Therapeutics, Inc.. Completed at 28 sites in 6 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-26.

Sponsored by Axsome Therapeutics, Inc. · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
59
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing solriamfetol in Disorders of Excessive Somnolence — 3 open to participants now, 3 under way, 2 of them phase 3. solriamfetol · Disorders of Excessive Somnolence.

Enrollment
8th of 12
59 · median 75
Started
2021
with 2 others
Phase 4
2 of 12
none open now
Registered
4th of 12
by date
Lead sponsor
4 of 12
Axsome Therapeutics, Inc.

Among the 12 studies testing solriamfetol in Disorders of Excessive Somnolence, this one is the 8th largest by enrollment, is one of 3 that started in 2021, is one of 2 in phase 4, and was the 4th registered.

Disorders of Excessive Somnolence

196 studies on the registry are indexed under Disorders of Excessive Somnolence; 34 are open to participants now.

Browse Disorders of Excessive Somnolence studies →

Open to participants now

3 of the 12 studies testing solriamfetol in Disorders of Excessive Somnolence are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About solriamfetol

solriamfetol: first FDA approval 2019 (SUNOSI), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 30 Disorders of Excessive Somnolence studies recruiting now, 12 (40%) set no upper age limit and 17 (57%) stop at 75 or younger; 5 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing solriamfetol in Disorders of Excessive Somnolence, or all of them as a file.
02

Study summary

The purpose of study JZP110-405 is to determine whether solriamfetol is effective at improving cognitive function in participants with excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA) plus impaired cognitive function.

03

Conditions studied

  • Excessive Daytime Sleepiness
  • Obstructive Sleep Apnea
  • Impaired Cognitive Function

Keywords

  • Axsome
  • SHARP
  • Solriamfetol
  • EDS
  • OSA
  • Cognition
  • Cognitive Function
  • DSST
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female between 18 (or the legal age of consent in the jurisdiction in which the study takes place) and 65 years of age, inclusive.
  2. Diagnosis of OSA according to International Classification of Sleep Disorders, Third Edition criteria.
  3. Participant report (with clinician concurrence) of at least 1 of the following primary OSA therapy criteria:

    • Consistent number of hours of primary PAP therapy use (with downloadable history) for OSA on at least 5 nights/week for at least 1 month prior to Baseline (with or without prior OSA surgical intervention), OR
    • No current use of PAP therapy for at least 1 month prior to Baseline but a history of at least 1 month of attempting to use PAP as the primary OSA therapy with at least 1 documented adjustment that was made in an attempt to optimize the therapy (with or without prior OSA surgical intervention), OR
    • History of a surgical intervention intended to treat OSA symptoms (with or without current PAP use as primary OSA therapy).
  4. Usual nightly total sleep time of ≥ 6 hours.
  5. from 18.5 to \< 40 kg/m2.
  6. Male participants are eligible to participate if they agree to the following during the study intervention period and for at least 14 days after the last dose of study intervention:

    • Refrain from donating sperm

    PLUS, either:

    • Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent OR
    • Must agree to use /barrier
  7. A female participant is eligible to participate if she is not pregnant or breastfeeding, and 1 of the following conditions applies:

    • Is a woman of nonchildbearing potential (WONCBP) OR
    • Is a and using a contraceptive method that is highly effective
  8. Capable of giving signed .

Exclusion criteria

Exclusion Criteria:

  1. Female participants who are pregnant, nursing, or lactating.
  2. Usual bedtime later than 1 AM (0100 hours).
  3. Occupation requiring nighttime or variable shift work.
  4. Unable to understand or perform DSST test per investigator's judgement.
  5. Use a PAP machine with no adherence data downloadable ability.
  6. Diagnosis of another sleep disorder (other than OSA) including: circadian rhythm sleep disorders, narcolepsy, restless legs syndrome determined by participant sleep history.
  7. Presence of acutely unstable major depression or current major depressive episode as based on the judgement of the investigator.
  8. Participants with active illness, including endocrine, neoplastic, gastrointestinal, hematological, hepatic, immunologic, metabolic, neurological, pulmonary, and/or renal disease, and/or surgical history which could interfere with the study efficacy, safety, conduct or the ability of the participant to complete the study based on the judgement of the investigator, or place the participant at risk during the trial or compromise the study objectives.
  9. History or presence of any other clinically relevant medical, behavioral, or psychiatric disorder other than OSA that is associated with an impact on cognitive function.
  10. History or presence of bipolar disorder, bipolar related disorders, schizophrenia, schizophrenia spectrum disorders, or other psychotic disorders according to , Fifth Edition (DSM-5) criteria.
  11. History of bariatric surgery within the past year or a history of any gastric bypass procedure.
  12. Participants with movement or motor disorders such as Parkinson's disease, as they will not be able to complete the DSST.
  13. Presence of renal impairment or calculated \< 60 mL/minute.
  14. Clinically significant abnormality in the opinion of the investigator.
  15. Presence of significant cardiovascular disease.
  16. Laboratory value(s) outside the laboratory reference range that is considered to be clinically significant by the investigator (clinical chemistry, hematology, and urinalysis). NOTE: Screening labs may be repeated once.
  17. Hypothyroidism or hyperthyroidism, unless stabilized by appropriate medication for at least 3 months prior to Screening (a normal thyroid-stimulating hormone is required prior to Randomization at Baseline).
  18. Use of any over-the-counter (OTC) or prescription medications that could affect the evaluation of EDS within a time period prior to the Baseline visit corresponding to at least 5 half-lives of the drug(s) or planned use of such drug(s) at some point throughout the duration of the 5-week double-blind treatment period.
  19. Current or recent (within the past 2 years) diagnosis of a moderate or severe substance use disorder (excluding caffeine) according to DSM-5 criteria, or seeking treatment for a substance-related disorder. Nicotine use disorder is excluded only if it has an effect on sleep (ie, a participant who routinely awakens at night to smoke).
  20. Excessive caffeine use.
  21. Urine drug screen positive for amphetamine, methamphetamine, tricyclic antidepressants, propoxyphene, benzodiazepines, barbiturates, cocaine, marijuana, morphine, ecstasy, oxycodone, buprenorphine, methadone, or phencyclidine at Screening or at any point throughout the duration of the study.
  22. History of regular heavy use of tetrahydrocannabinol (THC) is excluded. Sporadic recreational users of THC can complete a repeat urine drug screen during the Screening period. If this is negative, the participant may be allowed to enter the study pending agreement to completely refrain from the use of THC during the course of the study.
  23. Positive alcohol test at Screening.
  24. Participants who binge drink, defined as 5 or more drinks in a day for men or 4 or more drinks in a day for women at least once in past month.
  25. History of phenylketonuria or history of to phenylalanine-derived products.
  26. Currently receiving MAO inhibitors or having had received MAO inhibitors for 14 days prior to the Baseline visit.
  27. Previous exposure to solriamfetol.
  28. Received an drug in the past 30 days or 5 half-lives (whichever is longer) prior to the Baseline visit, or plans to use an investigational drug (other than the study drug) during the study.
  29. Is currently participating in another clinical study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
59 participants (actual)

Study arms

  • Active comparator
    Solriamfetol

    Solriamfetol 75 mg/d Solriamfetol 150 mg/d

    Drug: Solriamfetol

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Solriamfetol 75 mg/d Solriamfetol 150 mg/d

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Average of the DSST RBANS Scores at the End of Each Double-blind Treatment Period

    The DSST RBANS (Digit Symbol Substitution Test Repeatable Battery for the Assessment of Neuropsychological Status) is an objective neuropsychological test that assesses executive function, processing speed and attention. DSST RBANS scores range from a minimum of 0 (worse outcome) to a maximum of 100 (better outcome). The change from baseline was calculated as post-baseline - baseline. A positive change indicates improvement.

    Time frame: Baseline to the end of the second double-blind treatment period (up to 5 weeks)

07

Results

Posted Jan 26, 2026

Participant flow

Crossover Design: Subjects meeting the entry criteria were randomized in a 1:1 ratio either to Sequence 1 (up to 150 mg solriamfetol daily for two weeks followed by placebo for two weeks) or Sequence 2 (placebo for two weeks followed by up to 150 mg solriamfetol daily for two weeks). Crossover treatment periods were separated by a 1-week washout period.

Participant flow — Overall Study
MilestoneSequence 1Sequence 2
Started3029
Dosed with solriamfetol3029
Dosed with placebo3029
Mitt population2929
Completed2928
Not completed11

Outcome measures

PrimaryChange From Baseline in the Average of the DSST RBANS Scores at the End of Each Double-blind Treatment Period

The DSST RBANS (Digit Symbol Substitution Test Repeatable Battery for the Assessment of Neuropsychological Status) is an objective neuropsychological test that assesses executive function, processing speed and attention. DSST RBANS scores range from a minimum of 0 (worse outcome) to a maximum of 100 (better outcome). The change from baseline was calculated as post-baseline - baseline. A positive change indicates improvement.

Time frame:
Baseline to the end of the second double-blind treatment period (up to 5 weeks)
Reported as:
Least squares mean · score on a scale
Change From Baseline in the Average of the DSST RBANS Scores at the End of Each Double-blind Treatment Period
score on a scaleSolriamfetolPlacebo
Change From Baseline in the Average of the DSST RBANS Scores at the End of Each Double-blind Treatment Period6.49 ± 0.6504.75 ± 0.646
Statistical analysis
  • Solriamfetol vs Placebo · Mixed Models Analysis · p = 0.009 (P-value calculated from LSMean)

Adverse events

Collected over Adverse events were collected after administration of study drug through the final visit (up to 6 weeks).. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Solriamfetol0/59 (0%)0/59 (0%)6/59 (10.2%)
Placebo0/59 (0%)0/59 (0%)1/59 (1.7%)
Most frequent other events
Most frequent other events
EventSolriamfetolPlacebo
NauseaGastrointestinal disorders4/591/59
AnxietyPsychiatric disorders2/590/59

Baseline characteristics

Safety Population includes all subjects who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Sequence 1Sequence 2Total
Mean52.5 ± 10.4851.9 ± 11.1052.2 ± 10.70
Sex: Female, Male
Sex: Female, Male(Participants)Sequence 1Sequence 2Total
Female101121
Male201838
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sequence 1Sequence 2Total
American Indian or Alaska Native000
Asian123
Native Hawaiian or Other Pacific Islander000
Black or African American4812
White241943
More than one race000
Unknown or Not Reported101
08

Study locations

28 sites
  • Southern California Institute for Respiratory Disease
    Los Angeles, California 90048, United States
  • SDS Clinical Trials, Inc
    Santa Ana, California 92705, United States
  • Clinical Neuroscience Solutions, Inc
    Jacksonville, Florida 32256, United States
  • NeuroTrials Research Inc
    Atlanta, Georgia 30328, United States
  • The Neurological Center of north Georgia.
    Gainesville, Georgia 30501, United States
  • The Center for Sleep & Wake Disorders
    Chevy Chase, Maryland 20815, United States
  • Henry Ford Health System
    Novi, Michigan 48377, United States
  • Sleep Medicine & Research Center
    Chesterfield, Missouri 63017, United States
  • Advanced Respiratory and Sleep Medicine, PLLC
    Huntersville, North Carolina 28078, United States
  • CTI-Clinical Research Center
    Cincinnati, Ohio 45212, United States
  • Intrepid Research, LLC
    Cincinnati, Ohio 45245, United States
  • Bogan Sleep Consultants, LLC
    Columbia, South Carolina 29201, United States
  • FutureSearch Trials of Neuroglogy
    Austin, Texas 78731, United States
  • Sleep Therapy & Research Center
    San Antonio, Texas 78229, United States
  • Sleep and Performance Research Center
    Spokane, Washington 99202, United States
  • University of Calgary
    Calgary, Alberta T2N 4N1, Canada
  • MedSleep Inc. o/a Toronto Sleep Institute
    Toronto, Ontario M4P 1P2, Canada
  • Jodha Tishon Inc
    Toronto, Ontario M5S 3A3, Canada
  • IRCCS Istituto delle Scienze Neurologiche di Bologna
    Bologna, Emilia-Romagna 40139, Italy
  • IRCCS Ospedale San Raffaele - Servizio Farmacia
    Milan, Lombardy 20132, Italy
  • IRCCS Associazione Oasi Maria SS Onlus
    Troina, Sicily 94018, Italy
  • UOC Farmacia e Politiche del farmaco, edif 41
    Pisa, 56126, Italy
  • Amphia Hospital
    Breda, 4818 CK, Netherlands
  • Sleep-Waakcentrum SEIN
    Heemstede, 2104 SW, Netherlands
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
  • Hospital de la Santa Creu I Sant Pau
    Barcelona, 08041, Spain
  • Instiut de Reccerca Biomedica de Lledia
    Lleida, 25198, Spain
  • Royal Papworh Hospital
    Cambridge, CB23 3RE, United Kingdom
09

References and documents

Publications

  • Van Dongen HPA, Leary EB, Drake C, Bogan R, Jaeger J, Rosenberg R, Streicher C, Tabuteau H. Results of the Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-Controlled Study (SHARP): A Randomized Placebo-Controlled Double-Blind Repeated-Measures Crossover Phase IV Clinical Trial of the Effect of the Wake-Promoting Agent Solriamfetol on Cognitive Function in OSA With Excessive Daytime Sleepiness and Cognitive Impairment. Chest. 2025 Mar;167(3):863-875. doi: 10.1016/j.chest.2024.10.050. Epub 2024 Nov 9. PubMed 39528111 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2021 to primary completion in Sep 2022, 16 months.

Results were first posted in Jan 2026, 3 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2021
First posted
Mar 9, 2021
StartActual
May 17, 2021
Primary completionActual
Sep 19, 2022
CompletionActual
Sep 19, 2022
Results first posted
Jan 26, 2026
Last update
Jan 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04789174
Responsible party
Sponsor
First posted
Mar 9, 2021
Start date
May 17, 2021
Primary completion
Sep 19, 2022
Completion
Sep 19, 2022
Results posted
Jan 26, 2026
Last update
Jan 26, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solriamfetol

Start the discussion